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Abstract. Esophageal cancer is one of the most aggressive 
tumor types because of its invasiveness and metastatic poten-
tial. Several reports have described an association between 
increased invasiveness after ionizing radiation (IR) treatment 
and epithelial-to-mesenchymal transition (EMT). The bigu-
anide metformin is reported to prevent transforming growth 
factor-β (TGF-β)-induced EMT and proliferation of cancer. 
This study examined whether IR induces EMT and promotes 
the invasive potential of TE-9 esophageal squamous cell 
carcinoma cells and the effect of metformin on IR-induced 
EMT. After IR exposure, TE-9 cells showed a spindle-shaped 
morphology and lost cell-cell adhesion. Immunoblotting 
showed that IR induced expression of mesenchymal markers 
(vimentin and N-cadherin), transcription factors (Slug, Snail, 
and Twist), and matrix metalloproteinases. A scratch wound 
assay and Matrigel invasion assay showed that IR enhanced 
the invasive potential and migratory capacity of TE-9 cells. 
Expression of hypoxia-related factor-1α and TGF-β was 
increased after IR. IR also induced phosphorylation of 
Smad2 and Smad3. Metformin inhibited radiation-induced 
EMT-like morphological changes, and enhanced invasion 
and migration of TE-9 cells. Metformin inhibited IR-induced 
phosphorylation of Smad2 and Smad3. Although phosphory-
lation of AMP-activated protein kinase was enhanced by 
IR and metformin, phosphorylation of mammalian target of 
rapamycin was enhanced by IR and suppressed by metformin. 
These results indicated that metformin suppressed IR-induced 
EMT via suppression of the TGF-β-Smad phosphorylation 
pathway, and a part of the non-Smad pathway. Metformin 
might be useful to prevent IR-induced invasion and metastasis 
of esophageal squamous cell carcinoma.
Introduction
Esophageal cancer is a common malignancy among human 
gastrointestinal tumors. In 2008, it was estimated that 482,300 
new esophageal cancer cases and 406,800 deaths had occurred 
worldwide (1). In the most high-risk area, which stretches from 
Northern Iran through the central Asian republics to North-
Central China is called the esophageal cancer belt, 90% of the 
cases are squamous cell carcinoma. Esophageal cancer is one 
of the most aggressive types of tumor with an average 5-year 
survival rate of ~17% (2). It has been established that the rates 
of mortality and incidence of esophageal cancer are quite 
similar, probably because of the relatively late stage at diag-
nosis and rapid progression of the tumor. The treatment failure 
of esophageal cancer can be explained by the extensive local 
invasion and regional lymph node metastasis, which make it 
difficult to completely resect the tumors (2).
Chemoradiotherapy has an important role in the treatment 
of esophageal cancer in both inoperable and pre-operative 
settings (3). Even after complex multidisciplinary treatment, 
the rate of local recurrence and distant metastasis remains high. 
Acquired radioresistance during radiotherapy has been consid-
ered as one of the major reasons for treatment failure (4,5).
It has been reported that ionizing radiation (IR) activates 
multiple signaling pathways and affects the activity or abun-
dance of proteases, growth factors, cytokines, and adhesion 
proteins that are involved in tissue remodeling (6,7). Recently, 
several preclinical and clinical studies have shown that IR 
enhances the invasiveness and metastatic potential of human 
cancer cells. Tsukamoto et al (8) and Wild-Bode et al (9) 
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showed that sub-lethal doses of IR enhance the migration and 
invasiveness of human endometrial cancer and glioblastoma 
cells.
Recently, epithelial-to-mesenchymal transition (EMT) has 
been recognized as a key event in tumor invasion and metas-
tasis (10,11). EMT is a cellular process by which an epithelial 
cell changes its characteristics in response to both intracel-
lular and extracellular signaling pathways (12). It is a complex 
process that involves cytoskeletal remodeling, cell-cell and 
cell-matrix adhesions, and transcriptional regulation, leading 
to the transition from a polarized epithelial phenotype to an 
elongated fibroblastoid phenotype.
EMT is induced by multiple factors. Numerous studies have 
revealed that transforming growth factor-β (TGF-β) stimulates 
EMT in various types of cancer cells. TGF-β signals through 
a complex of two types of serine/threonine kinase receptors. It 
binds to the type II receptor and stimulates the type I receptor 
that activates the intracellular mediators Smad2 and Smad3 
by phosphorylation. Smad2 and Smad3 combine with Smad4 
to form complexes that translocate into the nucleus to activate 
gene expression related to EMT (12). IR can cause cancer cell 
death through apoptosis, senescence, and genomic instability. 
However, IR increases extra- and intracellular levels of TGF-β 
and induces acceleration of metastasis (8,13). Recently, radiation 
was found to enhance cell migration, invasion and metastasis 
through induction of EMT in various cancer cell lines including 
esophageal squamous cell carcinoma (ESCC) (11,14).
The biguanide metformin is the most widely used drug 
to treat type 2 diabetes. It reduces blood glucose levels by 
suppressing gluconeogenesis in the liver and increasing 
glucose uptake by skeletal muscle. It improves insulin sensi-
tivity and thus decreases insulin resistance. Activation of 
AMP-activated protein kinase (AMPK), an enzyme that is the 
central regulator of metabolic pathways, has been credited with 
the glucose-lowering effects of metformin (15). Retrospective 
epidemiological studies have provided evidence that type 2 
diabetic patients receiving metformin have substantially lower 
cancer incidence and mortality than those on other treat-
ments (16-18). Numerous preclinical and clinical studies have 
demonstrated multiple anticancer effects of metformin (19). 
Metformin has shown antigrowth effects in various tumor 
types using xenograft models (20). The main mechanism of 
tumor growth inhibition by metformin has been attributed to 
activation of AMPK, leading to various downstream effects 
that act together to restrain tumor growth (20-22). Metformin 
suppresses tumor growth by phosphorylation of AMPK, 
leading to suppression of mammalian target of rapamycin 
(mTOR) (20,22). Metformin has also been reported to prevent 
TGF-β-induced conversion of cancer cells into the migratory 
mesenchymal phenotype (23,24).
In this study, we examined whether IR induced EMT and 
enhanced the migration and invasiveness of ESCC cells. In 
addition, we investigated the possibility of metformin to 
prevent radiation-induced EMT in vitro.
Materials and methods
Cell lines and treatments. The human ESCC cell line TE9 was 
kindly provided by Dr Tetsuro Nishihira (Higashimatsuyama 
Medical Association Hospital, Saitama, Japan). The cells 
were cultured in RPMI-1640 (Gibco®, Life Technologies 
Corp., Tokyo, Japan) supplemented with 10% heat-inactivated 
fetal bovine serum (Nichirei Biosciences Inc., Tokyo, 
Japan), 100 IU/ml penicillin, 100 µg/ml streptomycin (Life 
Technologies Corp.), 2 mM glutamine (Nissui Pharmaceutical 
Co. Ltd., Tokyo, Japan) at 37˚C with 5% CO2.
Metformin (Wako Laboratory Chemicals, Tokyo, Japan) 
was dissolved in phosphate-buffered saline at a stock concen-
tration of 100 mM and stored at -20˚C. Cultures were irradiated 
using an MBR-1520R-3 (Hitachi Medicotechnology, Hitachi, 
Japan) at a dose rate of 0.66 Gy/min. The power output of the 
X-ray irradiation was 125 kV and 20 mA. Forward-scattered 
radiation 0.5 mm Al and 0.2 mm Cu filters were used.
Proliferation assay. The proliferation of cells treated with 
metformin was determined by a standard 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. TE9 
cells were seeded at a density of 4x103 cells/well in a 96-well 
culture plate and allowed to attach for 24 h. The cells were 
treated with metformin at various concentrations (0.1-5 mM) 
for 48 h. The percentage inhibition was determined by 
comparing the cell density of the drug-treated cells with that 
of untreated controls. All experiments were repeated at least 
three times.
Immunofluorescence. Cells were cultured on Lab-Tec chamber 
slides (Nalge Nunc International, New York, NY, USA). The 
medium was changed to serum-free medium after 24 h. The 
cells were treated with 0.5 mM metformin for 48 h and then 
irradiated (2 Gy). They were fixed in a mixture of methanol 
and acetone (1:1) for 5 min. The cells were blocked with 
1.5% bovine serum albumin and incubated with a mouse mono-
clonal antibody against vimentin (1:100 dilution; Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA) or a rabbit poly-
clonal antibody against E-cadherin (1:100 dilution; Santa Cruz 
Biotechnology, Inc.) and mouse monoclonal antibody against 
β-catenin (1:100 dilution; Santa Cruz Biotechnology Inc.) at 
4˚C overnight. The immunoreactivity was visualized by incu-
bating the cells with anti-rabbit IgG conjugated with Alexa 
Fluor 488 or 594 (Molecular Probes, Eugene, OR, USA) for 
1 h at room temperature. The cells were counterstained with 
bisbenzimide (Hoechst 33258, 100 ng/ml; Sigma-Aldrich Co., 
LCC) to visualize the nuclei. Finally, the cells were examined 
under an immunofluorescence microscope (BX50/BX-FLA, 
Olympus, Tokyo, Japan).
Scratch wound assay. TE9 cells were seeded at a density of 
1x105 in a 6-well plate and grown overnight to confluency. 
The monolayers of cells were scratched with a 1000-µl pipette 
tip to create a wound and then washed twice with serum-free 
RPMI-1640 to remove detached cells. The medium was then 
replaced with serum-free medium with or without 0.25 mM 
metformin, and the cells were irradiated (2 Gy). The rate of 
wound closure was assessed and photographed after 48 h. 
Each value was derived from three randomly selected fields.
Matrigel invasion assay. TE9 cells were treated with or without 
0.25 mM metformin after incubation in medium without FBS 
for 24 h. Then, the cells were irradiated (2 Gy) at 48 h after 
metformin treatment. The cells were collected by trypsiniza-
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tion, resuspended in serum-free medium at 1x105 cells/ml, 
and added to the upper chamber of a 24-well transwell insert 
(Corning Life Sciences, Corning, NY, USA) that was coated 
with 50 µl Matrigel (1:10 dilution in serum-free medium; 
BD Biosciences, Franklin Lakes, NJ, USA). Medium supple-
mented with 10% serum with or without 0.25 mM metformin 
was added to the bottom chamber. After 24 h, cells that had 
migrated through the Matrigel and 8-µm pore size membrane 
were fixed, stained and counted under a light microscope. All 
experiments were performed in triplicate.
Immunoblot analysis. Cell lysates were prepared in denaturing 
sodium dodecyl sulfate (SDS) sample buffer and subjected 
to SDS-polyacrylamide gel electrophoresis. Proteins (20 µg) 
from each sample were loaded onto a 10% polyacrylamide 
gel (Bio-Rad Laboratories, Hercules, CA, USA). The sepa-
rated proteins were transferred to polyvinylidene difluoride 
(PVDF) membranes (Bio-Rad Laboratories) and blocked with 
commercial gradient buffer (PVDF Blocking Reagent for 
Can Get Signal, Toyobo, Tokyo, Japan) at room temperature 
for 30 min. The membranes were incubated with the primary 
antibody overnight at 4˚C. After washing, the membranes were 
incubated with horseradish peroxidase-labeled anti-mouse or 
anti-rabbit IgG (GE Healthcare UK, Ltd., Buckinghamshire, 
UK) or anti-goat IgG (Santa Cruz Biotechnology, Inc.) for 
1 h at room temperature. Antibody-antigen complexes were 
detected using an ECL Plus kit (GE Healthcare Japan Co. Ltd.) 
and the Light Capture system (Atto Co. Ltd., Tokyo, Japan). 
Quantification was performed with the CS analyzer program 
(Atto Co. Ltd.). Primary antibodies used are described in 
Table I.
Results
Metformin inhibits the proliferation of TE9 cells. First, we 
examined the effects of metformin on cell proliferation using 
the MTT assay. Dose-dependent inhibition of proliferation 
was observed at 1-5 mM metformin (Fig. 1). Because 0.5 mM 
Table I. Primary antibodies used for immunoblot analysis.
Primary antibody  Isotype Dilution
Anti-E-cadherina H-108 Rabbit polyclonal IgG  1:2,000
Anti-vimentina V9 Mouse monoclonal IgG 1:2,000
Anti-N-cadherina H-63 Rabbit polyclonal IgG 1:1,000
Anti-β-catenina E-5 Mouse monoclonal IgG 1:1,000
Anti-Sluga H-140 Rabbit polyclonal IgG 1:400
Anti-twista H-81 Rabbit polyclonal IgG 1:500
Anti-TGF-β1a V Rabbit polyclonal IgG 1:500
Anti-phospho-Smad2/3a Ser 423/425 Goat polyclonal IgG 1:1,000
Anti-Smad2/3a E-20 Goat polyclonal IgG 1:1,000
Anti-Snailb C15D3 Rabbit monoclonal IgG 1:1,000
Anti-phospho-AMPKα (Thr172)b 40H9 Rabbit monoclonal IgG 1:2,000
Anti-AMPKαb D63G4 Rabbit monoclonal IgG 1:2,000
Anti-phospho-mTOR (Ser2448)b D9C2 Rabbit monoclonal IgG 1:2,000
Anti-mTORb 7C10 Rabbit monoclonal IgG 1:2,000
Anti-Raptorb 24C12 Rabbit monoclonal IgG 1:2,000
Anti-Rictorb 53A2 Rabbit monoclonal IgG 1:2,000
Anti-β-actinc  Mouse monoclonal IgG 1:10,000
Anti-HIF1αd H1α67 Mouse monoclonal IgG 1:500
Purchased from: aSanta Cruz Biotechnology Inc. (Santa Cruz, CA, USA); bCell Signaling Technology Inc. (Beverly, MA, USA); cSigma-
Aldrich Co. (Oakville, ON, Canada); dThermo Scientific Inc. (Wilmington, DE, USA).
Figure 1. Effect of metformin on cell proliferation. Effects of metformin on 
cell proliferation were assessed by an MTT assay. Data are expressed as the 
means ± SD of triplicate experiments. Statistically significant inhibition of 
cell proliferation after metformin exposure was observed at concentrations 
of 1 mM (77.3%, P=0.014), 2.5 mM (42.2%, P<0.001), and 5 mM (27.2%, 
P<0.001), but the inhibition did not reach statistical significance at 0.5 mM 
(93.0%, P=0.30).
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metformin did not significantly inhibit the growth of the cells, 
the majority of subsequent experiments were performed with 
0.25-0.5 mM metformin.
Metformin inhibits mesenchymal-like changes in esophageal 
cancer cells induced by IR. We examined morphological 
changes in TE-9 cells after 2 Gy IR. TE-9 cells showed loss 
of cell polarity, causing a spindle cell morphology, and 
enlargement between the cell-to-cell spaces at 48 h after IR. 
Pre-treatment with 0.5 mM metformin inhibited these morpho-
logical changes. Metformin did not induce any morphological 
changes when administered without IR compared with the 
control (Fig. 2).
Immunofluorescence analysis. Immunofluorescence analysis 
showed that IR induced vimentin (mesenchymal marker) 
expression and suppressed E-cadherin (epithelial marker) 
expression on the cell membrane of TE-9 cells. Pre-treatment 
with 0.5 mM metformin suppressed the vimentin expres-
sion induced after IR. Pretreatment with metformin also 
recovered E-cadherin expression to a level similar to that in 
the control (Fig. 3A). Expression of β-catenin (a cadherin-
associated protein) on the cell membrane was suppressed by 
IR. IR induced translocation of β-catenin to the cell nucleus. 
Metformin inhibited nuclear translocation of β-catenin 
induced by IR (Fig. 3B).
Metformin inhibits cell migration and invasion promoted by 
IR. We analyzed the migratory and invasive phenotypes of 
TE-9 cells using scratch wound and Matrigel invasion assays. 
As shown in Fig. 4A, the scratch wound assay indicated that 
the migration of TE-9 cells was significantly stimulated by 
IR. Metformin itself did not affect the migratory phenotype 
of the cells. Pretreatment with 0.25 mM metformin inhibited 
IR-induced migration in TE-9 cells (Fig. 4B). Similarly, the 
data obtained from the Matrigel invasion assay showed that 
IR stimulated cell invasion. Pretreatment with 0.25 mM 
metformin inhibited the IR-induced invasive phenotype of 
the cells (Fig. 5). Next, we examined the expression of matrix 
metalloproteinase (MMP)-associated proteins, which are 
related to the invasion and metastasis of esophageal cancer 
(25). In the immunoblotting analysis, MMP-2/7/9 expression 
was increased by IR. Pretreatment with metformin reduced 
the IR-induced enhancement of MMP expression (Fig. 6A).
Effect of metformin on EMT-associated signaling pathways 
induced by IR. Expression of mesenchymal marker proteins 
(vimentin and N-cadherin) was increased by IR in compar-
ison with the control. Metformin counteracted the effects 
of IR on mesenchymal marker protein expression. There 
were no apparent differences in the expression of epithelial 
markers E-cadherin and β-catenin between the metformin-
treated and IR groups (Fig. 6B). Snail, Slug, and Twist are 
EMT-associated transcription factors. The expression of 
these proteins was elevated in the IR group compared with 
the control group. After the addition of metformin, protein 
expression of these transcription factors was suppressed 
following IR exposure (Fig. 6B). Increased expression of 
hypoxia-related factor (HIF)-1α was found at 48 h after 
IR treatment. Metformin had no effect on the increase 
in HIF-1α expression after IR exposure. TGF-β1 expres-
sion was also increased in the IR group, but the increased 
expression of TGF-β1 was not suppressed by metformin. 
Metformin suppressed radiation-induced phosphorylation 
of Smad2/3 (Fig. 6C). Phosphorylation of AMPK was found 
after metformin treatment, irrespective of IR exposure. 
Figure 2. Morphological changes after ionizing radiation (IR) and metformin (Met) treatments. TE-9 cells were treated with 0.5 mM metformin for 48 h and 
then 2 Gy IR, followed by observation under a phase contrast microscope. Scale bar, 10 µm.
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Phosphorylation of mTOR was enhanced in the IR group, but 
it was significantly reduced in the metformin-treated group. 
Expression of a component of mTORc1, Raptor, was elevated 
in the IR group (Fig. 6C).
Figure 3. Immunofluorescence analysis after ionizing radiation (IR) and metformin (Met) treatments. TE-9 cells were treated with 0.5 mM metformin for 48 h 
and/or 2 Gy IR. Immunofluorescence analysis of E-cadherin, vimentin (A), and β-catenin (B) expression was performed. TE-9 cells were fixed and stained with 
bisbenzimide (blue). Expression of vimentin (green), E-cadherin (red), and β-catenin (green) was examined by immunofluorescence analysis. Representative 
images of multiple fields are shown for each treatment group. Scale bar, 10 µm.
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Discussion
This study showed that IR induces EMT and promotes migra-
tion and invasion potential in TE-9 ESCC cells and metformin 
inhibits IR-induced EMT.
In several studies, IR has induced EMT that occurs at the 
time of initiation of metastasis, leading to cancer progression, 
and is associated with the development of resistance to radio-
therapy (10,11). In this study, we found that TE-9 cells changed 
their morphology to a spindle shape and lost cell-cell adhe-
sion after IR exposure. Immunofluorescence and immunoblot 
analyses showed that IR induced expression of mesenchymal 
markers vimentin and N-cadherin as well as nuclear localiza-
tion of β-catenin in TE-9 cells. These results indicate that a 
sub-lethal dose of IR can induce EMT in ESCC. We have 
already confirmed these phenomena using several other ESCC 
cell lines (data not shown). Although IR did not reduce the 
total amount of epithelial marker E-cadherin, the distribution 
of E-cadherin was changed from the cell membrane to the 
cytoplasm. During the EMT process, expression of E-cadherin 
is repressed through transcriptional reduction. E-cadherin 
translocates from the cell surface by endocytosis and is 
degraded by a proteasome (26). Cytoplasmic localization of 
E-cadherin without a decrease in the total protein amount 
shown in this study might suggest the degradation process of 
E-cadherin during EMT. Furthermore, we found upregulation 
of transcription factors, including Slug, Snail, and Twist, which 
regulate EMT (12). The effect of TGF-β on EMT has been 
Figure 4. Effect of ionizing radiation (IR) and metformin (Met) on the migration of TE-9 cells. (A) Representative images of the migration assay (scratch wound 
assay). Cell monolayers were scratched with a pipette tip and then treated with 0.25 mM metformin for 48 h and then 2 Gy irradiation. Migrating cells were 
photographed under a phase contrast microscope. (B) Migration (% migration) was calculated by the following formula: (pretreatment wound width - width 
after 48 h) / pretreatment width x 100. Data are expressed as the means ± SD of triplicate experiments. **Significantly different from the control (P<0.001).
Figure 5. Effect of ionizing radiation (IR) and metformin (Met) on the invasion of TE-9 cells. (A) Representative images of the invasion assay. Cells were 
treated with 0.25 mM metformin or the vehicle for 48 h. At 48 h after irradiation (2 Gy), the invasive ability of the cells was examined by a Matrigel invasion 
assay. (B) Invaded cells on the lower surface of the filter were counted. Data are expressed as the means ± SD of triplicate experiments. *Significantly different 
from the control (P=0.003).
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identified in a variety of cancer types (27,28). We confirmed 
that TGF-β stimulation also induced EMT by morphological 
changes, enhancement of mesenchymal markers, and β-catenin 
translocation to the nucleus in TE-9 cells (data not shown).
To clarify the mechanisms of EMT induced by IR, we 
focused on HIF-1α expression in this study. Radiation causes 
hypoxia in cancer cells and the surrounding microenviron-
ment (6,7). Hypoxia induces various cytokines and growth 
factors including HIF-1α in cancer cells. These cytokines 
increase angiogenesis, self-renewal, and cancer stem cell-like 
characteristics (6,7,29). We found that IR induced HIF-1α and 
TGF-β expression. Subsequently, phosphorylation of Smad2/3 
was increased. TGF-β family proteins signal through Smads 
that combine with DNA sequence-specific transcription 
factors to activate or repress transcription. The Smad pathway, 
which, in the case of TGF-β, is mediated by Smad2 and Smad3 
in combination with Smad4, is considered to be the major 
TGF-β family signaling pathway and accounts for the many 
changes in gene expression observed in response to TGF-β 
family proteins (12,27,30). However, various EMT pathways 
have been reported to be induced by TGF-β. These are called 
non-Smad signaling pathways and include activation of Erk 
Map kinase, Rho GTPases and PI3 kinase/Akt pathways. 
These pathways have been linked to TGF-β-induced EMT 
through their regulation of distinct processes such as cyto-
skeleton organization, cell growth, survival, migration and 
invasion (12,27). Through PI3 kinase/Akt pathways, mTOR/
S6 kinase 1 is activated in the mammary gland cells of mice 
by TGF-β-induced EMT (12,30). In this study, we found that 
IR induced mTOR phosphorylation, suggesting activation of 
non-Smad signaling pathways. These results indicate that IR 
induces EMT through activation of TGF-β family signaling 
pathways including Smad and non-Smad pathways in TE-9 
cells.
As a result of mesenchymal transition, β-catenin (the 
lining protein of E-cadherin) changes its localization from 
the cell membrane to the nucleus. The transcription of cell 
invasion-related protein MMP-7 has been reported to be 
controlled by nuclear translocation of β-catenin (31). We also 
found enhanced expression of MMPs, including MMP7, after 
IR exposure. We confirmed enhancement of the invasive 
potential and migratory capacity of esophageal cancer cells 
by IR using scratch wound and Matrigel invasion assays. It has 
been reported that radiation-induced EMT causes radiation 
resistance and enhances the migration-invasive potential with 
increases of MMPs in several types of cancer cells (9,11,14,32).
We found that metformin inhibited IR-induced EMT 
in association with the invasive and migratory phenotypes 
Figure 6. Effects of ionizing radiation (IR) and metformin (Met) on the expression of MMPs and EMT-related factors. Cells were pretreated with 0.25 mM 
metformin or the vehicle for 48 h. Soluble lysates from untreated or irradiated cells were prepared at 48 h after irradiation (2 Gy) and analyzed for expression 
of MMPs (A), EMT markers and EMT-associated transcription factors (B), and EMT-associated signaling factors (C) by immunoblot analysis.
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of ESCC cells. To elucidate the mechanism by which 
metformin inhibited EMT enhanced by IR, we investigated 
cell morphology and alterations of EMT-associated proteins 
by metformin after IR. The cells treated with metformin did 
not show the EMT-like morphological changes caused by IR. 
The enhancements in the expression of mesenchymal markers 
(vimentin and N-cadherin), EMT-associated transcription 
factors (Snail, Slug, and Twist), and MMPs after IR were 
suppressed by metformin. However, increased expression of 
HIF-1α and TGF-β by IR was not inhibited by metformin. 
Therefore, metformin might suppress radiation-induced EMT 
by inhibition of TGF-β signaling pathways. The fact that 
metformin suppressed radiation-induced Smad2/3 and mTOR 
phosphorylation support this hypothesis. Recently, several 
studies have indicated that metformin suppresses proliferation, 
migration, and EMT by inhibition of mTOR signaling (33,34). 
Metformin has also been reported to suppress EMT induced 
by TGF-β administration in breast and lung cancer cells 
(23,24,35).
Originally, metformin was found to inhibit complex I of 
the mitochondria respiratory chain and increase the propor-
tion of AMP in cells. Furthermore, it reduces blood glucose 
and improves glucose tolerance and insulin resistance by 
activation of AMPK (15). Increasing evidence suggests that 
the antitumor effect of metformin might be linked to its 
direct and indirect mechanisms. The indirect mechanisms of 
metformin, which are considered as insulin dependent, include 
enhancement of insulin sensitivity and reductions in the blood 
levels of glucose and insulin, resulting in the inhibition of the 
insulin/insulin-like growth factor-1 signaling pathway, and 
eventually resulting in the inhibition of tumor cell growth. 
Its direct mechanisms, which are considered as insulin inde-
pendent, include primarily activation of AMPK, a central 
energy sensor, in turn leading to inhibition of the mTOR 
signaling pathway. Specifically, when the level of cellular ATP 
decreases, resulting in an increase in the ratio of AMP/ATP, 
AMPK is activated, contributing to inactivation of the Akt/
mTOR signaling mediated through the inhibition of mTOR by 
activation of LKB1, a known tumor suppressor. The inhibition 
of mTOR activity leads to the inhibition of glucose synthesis 
in the liver and protein synthesis, contributing to the inhibition 
of cell growth/proliferation of tumor cells mediated through 
the reduction in the bioavailability of intracellular energy 
and nutrients such as glucose and amino acids. Moreover, 
metformin can directly inhibit tumor cell growth/proliferation 
via modulation of the cyclin D1-medicated cell cycle and the 
expression of tumor suppressor p53 in various tumor cell types 
including pancreatic and breast cancers (20-22). In this study, 
we found the 0.5 mM metformin, which do not have a direct 
inhibitory effect on ESCC cell growth, suppressed IR-induced 
EMT, leading to less cell invasion after IR.
IR activates AMPK acutely in epithelial cancer cell 
cultures to transduce signals through a DNA damage response-
mediated ataxia teleangiectasia-mutated-AMPK-p53-p21cip1 
axis, and mediate cell cycle arrest and radiosensitization 
(36,37). However, IR also activates molecular pathways of 
tumor radioresistance, such as the Akt/mTOR pathway (38). 
mTOR stimulates growth of cellular biomass, proliferation, 
and resistance to cytotoxic agents (20). As shown in this study, 
a sub-lethal dose of IR induced mTOR phosphorylation and 
EMT. Metformin activated AMPK by phosphorylation and 
suppressed phosphorylation of mTOR induced by IR.
Most in vitro studies investigating anticancer effect of 
metformin have used metformin at a dose between 1 and 
10 mM (165-1650  mg/l), which is beyond the therapeutic 
plasma levels (0.465-2.5 mg/l or 2.8-15 µM) (19). We examined 
the effects of metformin on cell proliferation and cytotoxicity. 
It was found that metformin showed no significant cytostatic 
effect at 0.25-0.5 mM. In this study, the inhibitory effect of 
metformin against radiation-induced EMT was examined at 
a higher concentration than the clinically therapeutic plasma 
levels. Recently, it has been reported that low-dose metformin 
(2.5 µM-5 mM) inhibits proliferation and enhances radio-
sensitivity in lung cancer cells (37). Further study should 
be performed to clarify the possibility of clinical usage of 
metformin by examining its effect at lower doses.
Metformin has a long track record as a diabetic drug, and its 
efficacy and side-effects have been fully discussed previously 
(15). Its most common toxicity is mild-to-moderate gastro-
intestinal discomfort, usually self-limited and ameliorated 
by a graduated ramp up in dose. The most serious toxicity 
of metformin, lactic acidosis, is rare, occurring once per 
100,000 years of use (39). Metformin alone is rarely associated 
with hypoglycemia. According to a recent review, the reported 
risks of hypoglycemia for metformin users vary between 
0 and 21%. Because metformin does not directly stimulate 
insulin secretion, the hypoglycemic risk may be lower than for 
that of other oral antidiabetic drugs (39).
Prospective data regarding metformin use in non-diabetic 
cancer patients are beginning to emerge (40,41). Completion 
of these studies, as well as planned and ongoing studies on 
the metastatic and adjuvant setting in breast, prostate, pancre-
atic and endometrial cancers (clinicaltrials.gov), will provide 
important additional information on the anticancer effects of 
metformin and help elucidate the clinically important mecha-
nisms of metformin action in diabetic and non-diabetic cancer 
patients.
In this study, metformin inhibited IR-induced invasion and 
migration of esophageal cancer cells by inhibition of EMT via 
suppression of TGF-β signaling pathways. Metformin might 
be beneficial to use during radiation therapy for esophageal 
cancer to prevent invasion and metastasis caused by IR-induced 
EMT. To confirm the clinical availability of metformin in 
radiotherapy, further studies are needed.
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